Literature DB >> 27890167

Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.

Marcia A Friedman1, Kevin L Winthrop2.   

Abstract

Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis-specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues." Published by Elsevier Inc.

Entities:  

Keywords:  Anti-TNF; Biologic; DMARD; Efficacy; Immunogenicity; Rheumatoid arthritis; Rituximab; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27890167     DOI: 10.1016/j.rdc.2016.09.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  15 in total

Review 1.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422

2.  Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination.

Authors:  Neha Kumar; Kelsey Graven; Nancy I Joseph; John Johnson; Scott Fulton; Robert Hostoffer; Hesham Abboud
Journal:  Int J MS Care       Date:  2020 Mar-Apr

3.  Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.

Authors:  Ayelet Grupper; Liane Rabinowich; Doron Schwartz; Idit F Schwartz; Merav Ben-Yehoyada; Moshe Shashar; Eugene Katchman; Tami Halperin; Dan Turner; Yaacov Goykhman; Oren Shibolet; Sharon Levy; Inbal Houri; Roni Baruch; Helena Katchman
Journal:  Am J Transplant       Date:  2021-05-07       Impact factor: 9.369

Review 4.  Current perspective on rituximab in rheumatic diseases.

Authors:  Tommaso Schioppo; Francesca Ingegnoli
Journal:  Drug Des Devel Ther       Date:  2017-10-03       Impact factor: 4.162

Review 5.  Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.

Authors:  Jean-Luc Davignon; Benjamin Rauwel; Yannick Degboé; Arnaud Constantin; Jean-Fredéric Boyer; Andrey Kruglov; Alain Cantagrel
Journal:  Arthritis Res Ther       Date:  2018-10-12       Impact factor: 5.156

6.  Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.

Authors:  Clarissa de Castro Ferreira; Ana Carolina Campi-Azevedo; Vanessa Peruhype-Magalhāes; Jordana Grazziela Coelho-Dos-Reis; Lis Ribeiro do Valle Antonelli; Karen Torres; Larissa Chaves Freire; Ismael Artur da Costa-Rocha; Ana Cristina Vanderley Oliveira; Maria de Lourdes de Sousa Maia; Sheila Maria Barbosa de Lima; Carla Magda Domingues; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Lícia Maria Henrique da Mota
Journal:  Arthritis Res Ther       Date:  2019-03-14       Impact factor: 5.156

7.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

Review 8.  Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).

Authors:  Cara D Varley; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2021-07-16       Impact factor: 4.592

Review 9.  Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review.

Authors:  Byung-Soo Kim; Emanual Maverakis; Clarie Alexanian; Jenny Z Wang; Siba P Raychaudhuri
Journal:  J Cutan Med Surg       Date:  2020-04-02       Impact factor: 2.092

10.  The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.

Authors:  Mikhail M Kostik; Natalia A Lubimova; Irina V Fridman; Olga V Goleva; Susanna M Kharit
Journal:  Pediatr Rheumatol Online J       Date:  2021-07-05       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.